UNION is a clinical-stage, diversified biotechnology company focusing on immunology and infectious diseases. Our current portfolio is comprised of two medicinal compound classes with proven modes of action that support significant potential to address unmet medical needs.

UNION has raised funds through non-dilutive sources, the European Investment Bank as well as through equity. Key shareholders are founders, management, family offices and private investors.

At UNION, we are committed to providing reliable and transparent information about our business, development programs and scientific results in a clear and timely manner.

For more information, please contact: 

Morten Boesen, CFO
[email protected]
+45 2381 5487